Related Experiment Video
Updated: May 26, 2025

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
Published on: July 12, 2024
Ambient Air Pollution and Parkinson's Disease and Alzheimer's Disease: An Updated Meta-Analysis
Cuiyao Xie1,2,3,4, Xi Xia1,2,3,4, Kai Wang1,2,3,4
1Department of Occupational and Environmental Health, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China.
Background:
Previous epidemiological evidence regarding the associations between ambient air pollution and two major neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD), remains inconclusive.
Objective:
This study aimed to evaluate the associations between long-term and short-term exposure to PM2.5 and PM10 (i.e., particulate matter with an aerodynamic diameter of, or smaller than, 2.5 μm or 10 μm), nitrogen dioxide (NO2), ozone, sulfur dioxide, and carbon monoxide and the risks of AD and PD.
Methods:
A random-effects model was used to summarize individual effect estimates in the meta-analysis. A subgroup meta-analysis was further conducted to explore the potential sources of heterogeneity.
Results:
In total, 42 eligible studies were included. For each 5 μg/m3 increase in long-term PM2.5 exposure, the odds ratios (ORs) were 1.16 (95% CI: 1.04, 1.30; I2 = 95%) and 1.10 (95% CI: 1.03, 1.17; I2 = 95%) for AD and PD, respectively. For each 5 μg/m3 increase in short-term PM2.5 exposure, the OR was 1.01 (95% CI: 1.002, 1.01; I2 = 77%) for PD. For each 1 ppb increase in long-term NO2 exposure, the OR was 1.01 (95% CI: 1.0002, 1.02; I2 = 79%) for PD.
Conclusion:
Ambient air pollution, particularly PM2.5, may contribute to the increased risks of neurodegenerative diseases including AD and PD.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Alzheimer's Disease: Treatment

